Compugen Ltd. To Disclose Novel Cancer Immunotherapy Target Candidate And Comprehensive Target Characterization Infrastructure At Today’s Analyst And Investor Day

TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, will disclose an additional novel immune checkpoint target candidate, CGEN-15029, and initial experimental validation data for this candidate at its Analyst and Investor Day in New York City today. In addition, the Company will disclose a new computational infrastructure, LINKS, which is designed for the comprehensive and comparative assessment of drug targets. Initial usage of this new infrastructure resulted in the selection of five target candidates, including CGEN-15029, as the highest priority immune checkpoint target programs to be advanced by the Company.

Help employers find you! Check out all the jobs and post your resume.

Back to news